Skip to content
Screener

EBITDA at other companies

Eli Lilly logo
Eli LillyLLY
$9.78B+34.8%
Gilead Sciences logo
Gilead SciencesGILD
-$10.3B-501%
Relay Therapeutics, Inc. logo
Relay Therapeutics, Inc.RLAY
-$90.46M-19.3%
Immunome logo
ImmunomeIMNM
-$58.73M-33.4%
Oric Pharmaceuticals, Inc. logo
Oric Pharmaceuticals, Inc.ORIC
-$39.35M-21.4%
BridgeBio Pharma logo
BridgeBio PharmaBBIO

Other financials

Income statement

See full
Operating income-$50.5M-39.8%
Net income-$52.8M-42.8%
EPS (diluted)-$0.97-12.8%

Balance sheet

See full
Cash & equivalents$145.2M+781%
Total debt$137.9M+30.7%
Total equity$53.5M-38.2%
Total assets$410.2M+88.0%

Cash flow

See full
Operating cash flow-$55.1M-53.6%
CapEx$249.0K+315%
Free cash flow-$55.3M-54.0%

Valuation

See full
Market cap$4.55B+150%
Enterprise value$4.54B+142%

Returns & leverage

See full
Return on equity-275.2%-990pp
Debt / equity2.6×+1.4×
Current ratio12.3×+5.7×

Where this comes from

Calculated from Celcuity’s reported figures.

$50.5Mebit+
$47.0KDepreciation Depletion & Amortization
=-$50.46M

The source filing: Celcuity’s 10-Q, filed May 14, 2026. Open the filing →

Filed
May 14, 2026, 5:15 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001493152-26-023180

FAQ

What is Celcuity's EBITDA?
Celcuity (CELC) reported EBITDA of -$50.46M in Q1 2026.
How has Celcuity's EBITDA changed year-over-year?
Celcuity's EBITDA decreased by 39.8% year-over-year, from -$36.1M to -$50.46M.
What is the long-term trend for Celcuity's EBITDA?
Over 4 years (2021 to 2025), Celcuity's EBITDA has grown at a 57.4% compound annual growth rate (CAGR), from -$28.05M to -$172.03M.
What does EBITDA mean?
Earnings before interest, taxes, depreciation, and amortization — EBIT plus the D&A add-back from the cash-flow statement (EBITDA = EBIT + D&A). A proxy for cash earnings that strips out financing, tax, and non-cash charges.

Ask your AI about Celcuity's ebitda.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude